AdipoPharma
Biotechnology company developing an adipocyte-targeted, stapled peptide therapeutic to treat insulin resistance, type 2 diabetes and associated metabolic comorbidities. Research is driven by genetic studies of rare metabolic disorders and preclinical in vivo studies showing improvements in glucose handling, insulin sensitivity, and liver pathology. The lead candidate is scheduled to enter clinical trials in 2025.
Industries
Nr. of Employees
small (1-50)
Products
Adipocyte-targeted stapled peptide therapeutic (lead candidate)
A macrocyclic peptide biologic designed to act on adipose tissue to restore healthy lipid biosynthesis, reduce toxic lipids (e.g., ceramides), improve glucose uptake and insulin sensitivity, and mitigate liver fibrosis and cardiovascular risk factors; lead candidate planned to enter clinical trials in 2025.
PATAS
PATAS is an innovative peptide that targets a specific protein-protein interaction of ALMS1 in the adipocyte, triggering insulin-independent glucose absorption and providing significant systemic metabolic benefits.
Adipocyte-targeted stapled peptide therapeutic (lead candidate)
A macrocyclic peptide biologic designed to act on adipose tissue to restore healthy lipid biosynthesis, reduce toxic lipids (e.g., ceramides), improve glucose uptake and insulin sensitivity, and mitigate liver fibrosis and cardiovascular risk factors; lead candidate planned to enter clinical trials in 2025.
PATAS
PATAS is an innovative peptide that targets a specific protein-protein interaction of ALMS1 in the adipocyte, triggering insulin-independent glucose absorption and providing significant systemic metabolic benefits.
Services
Partnerships with academic and industry groups to co-develop peptide-based metabolic therapeutics and advance preclinical programs.
Partnerships with academic and industry groups to co-develop peptide-based metabolic therapeutics and advance preclinical programs.
Expertise Areas
- Adipocyte biology and metabolic disease
- Peptide therapeutics development
- Preclinical metabolic pharmacology
- Biomarker discovery from genetic studies
Key Technologies
- Stapled/macrocyclic peptide therapeutics
- In vivo preclinical metabolic models
- Lipidomics / ceramide analysis
- Biomolecular NMR
News & Updates
Company states its lead adipocyte-targeted peptide therapeutic will enter clinical trial phases in 2025.
Peer-reviewed article examining adipose tissue failure and its role in insulin resistance; linked work underlying target identification.
Preclinical study reporting improvements in whole-body insulin resistance and metabolic comorbidities following treatment with the lead peptide candidate.
Article on ciliogenesis during adipogenic differentiation relevant to adipocyte biology.
Study on ciliary defects and adipogenesis with implications for metabolic research.
Company states its lead adipocyte-targeted peptide therapeutic will enter clinical trial phases in 2025.
Peer-reviewed article examining adipose tissue failure and its role in insulin resistance; linked work underlying target identification.
Preclinical study reporting improvements in whole-body insulin resistance and metabolic comorbidities following treatment with the lead peptide candidate.
Article on ciliogenesis during adipogenic differentiation relevant to adipocyte biology.
Study on ciliary defects and adipogenesis with implications for metabolic research.